| Graft-versus-host disease |
2.05 |
0.00e+0 |
32/42 (76.19%) |
HLA-F;HLA-C;HLA-DPB1;...
|
| Complement and coagulation cascades |
2.04 |
5.27e-3 |
76/85 (89.41%) |
C1QA;C1QB;C3;...
|
| Antigen processing and presentation |
2.00 |
1.41e-2 |
60/78 (76.92%) |
CALR;HLA-F;IFI30;...
|
| Pertussis |
1.99 |
1.05e-2 |
64/76 (84.21%) |
C1QA;C1QB;C3;...
|
| Allograft rejection |
1.89 |
1.69e-2 |
32/38 (84.21%) |
HLA-F;HLA-C;HLA-DPB1;...
|
| Systemic lupus erythematosus |
1.89 |
1.41e-2 |
45/135 (33.33%) |
C1QA;C1QB;C3;...
|
| Epstein-Barr virus infection |
1.88 |
1.21e-2 |
189/202 (93.56%) |
CXCL10;CALR;HLA-F;...
|
| Viral carcinogenesis |
1.87 |
1.05e-2 |
149/203 (73.4%) |
C3;HLA-F;PKM;...
|
| Autoimmune thyroid disease |
1.85 |
1.29e-2 |
46/53 (86.79%) |
HLA-F;HLA-C;HLA-DPB1;...
|
| Toll-like receptor signaling pathway |
1.84 |
1.16e-2 |
94/104 (90.38%) |
CXCL9;CXCL10;TLR2;...
|
| Viral myocarditis |
1.83 |
1.15e-2 |
53/60 (88.33%) |
HLA-F;DMD;HLA-C;...
|
| JAK-STAT signaling pathway |
1.82 |
1.14e-2 |
146/162 (90.12%) |
IL6R;IL7R;SOCS5;...
|
| Herpes simplex virus 1 infection |
1.78 |
2.19e-2 |
165/498 (33.13%) |
C3;CALR;HLA-F;...
|
| Type I diabetes mellitus |
1.78 |
2.11e-2 |
38/43 (88.37%) |
HLA-F;HLA-C;HLA-DPB1;...
|
| Staphylococcus aureus infection |
1.72 |
3.30e-2 |
72/95 (75.79%) |
C1QA;C1QB;KRT18;...
|
| Hepatitis C |
1.68 |
4.48e-2 |
139/157 (88.54%) |
CXCL10;MX2;TNFRSF1A;...
|
| Tuberculosis |
1.68 |
4.41e-2 |
159/180 (88.33%) |
C3;TLR2;ITGB2;...
|
| Proteasome |
1.66 |
4.75e-2 |
44/46 (95.65%) |
PSMB9;PSMB3;PSMC4;...
|
| AMPK signaling pathway |
1.65 |
4.66e-2 |
106/120 (88.33%) |
EIF4EBP1;FASN;CD36;...
|
| Oxidative phosphorylation |
-1.75 |
4.17e-2 |
93/133 (69.92%) |
NDUFS8;NDUFA4;COX5B;...
|
| Valine, leucine and isoleucine degradation |
-1.78 |
4.51e-2 |
42/48 (87.5%) |
ACAA1;HADHB;BCAT1;...
|
| Propanoate metabolism |
-1.81 |
4.74e-2 |
30/34 (88.24%) |
LDHC;EHHADH;SUCLG2;...
|
| Endocrine and other factor-regulated calcium reabsorpti... |
-1.88 |
4.74e-2 |
49/53 (92.45%) |
ESR1;ADCY9;GNAS;...
|
